Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615772 | 0.94 | HTR6 (0.40) | HTR6DRD2DRD4DRD3CA2 | |
| SCHEMBL4617179 | 0.92 | HTT (0.45) | HTR6ACHEDRD2DRD4DRD3 | |
| SCHEMBL4636515 | 0.92 | DRD2 (0.49) | HTR6ACHEDRD2DRD4DRD3 | |
| SCHEMBL4617544 | 0.89 | DRD2 (0.48) | HTR6DRD2DRD3CA2 | |
| SCHEMBL4617526 | 0.87 | DRD2 (0.43) | HTR6DRD2 | |
| SCHEMBL4617689 | 0.87 | DRD2 (0.44) | HTR6DRD2 | |
| SCHEMBL5321325 | 0.86 | DRD2 (0.42) | HTR6DRD2SMN1; SMN2 | |
| SCHEMBL4616556 | 0.84 | ACHE (0.42) | ACHEBACE1DRD2DRD4DRD3 | |
| SCHEMBL27679086 | 0.78 | HTT (0.44) | HTR6ACHEDRD2DRD4DRD3 | |
| SCHEMBL27698157 | 0.78 | DRD2 (0.46) | HTR6ACHEDRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | H. LUNDBECK A/S (DK) | 2008-06-12 | — | — | US | disclosed |
| US-7329656-B2 | Arylthiobenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-02-12 | — | — | US | disclosed |
| EP-1799223-A4 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | LUNDBECK & CO AS H (DK) | 2008-01-23 | — | — | EP | disclosed |
| EP-1799223-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | H.Lundbeck A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006041635-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079523-A1 | N-[3-(1-{[4-(4-fluorophenylthio)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide; melatonin-concentrating hormone (MCH1) receptor ligand; antidepressant, anxiolytic, antidiabetic agent | MCHR1, MTNR1A, MTNR1B | HTR6 25/4885ACHE 2866/4885BACE1 4055/4885 |
| US-20080139555-A1 | Arylthiobenzylpiperidine Derivatives | MCHR1, MC4R, MCHR2 | HTR6 25/4885ACHE 2682/4885BACE1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.